<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141250">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01931683</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-CT4-13</org_study_id>
    <nct_id>NCT01931683</nct_id>
  </id_info>
  <brief_title>Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)</brief_title>
  <official_title>Effect-site Concentration of Remifentanil for Smooth Removal of the LMA From Propofol Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators attempted to determine the optimal effect-site concentration of
      remifentanil for smooth removal of the LMA from propofol anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to
      predetermined (initial concentration 1.0 ng/ml for the first patient). LMA removal was
      performed when the patients opened their eyes and spontaneous respiration and adequate tidal
      volume and ventilatory frequency were confirmed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>smooth removal of LMA</measure>
    <time_frame>from end of surgery to removal of LMA (participants will be followed for the emergence periods, an expected average of 15 min).</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the response of patients to the removal of LMA (classified as either 'success [smooth emergence]' or 'failure') during infusion of remifentanil.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Drug Usage</condition>
  <arm_group>
    <arm_group_label>remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)</description>
    <arm_group_label>remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>laryngeal mask airway (LMA)</intervention_name>
    <description>LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed</description>
    <arm_group_label>remifentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II patients undergoing general anesthesia for short elective surgery (&lt;1 hr)

        Exclusion Criteria:

          -  G-E reflux

          -  obesity (BMI&gt;30)

          -  anticipated difficult airway
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Yeop Kim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Yeop Kim, MD</last_name>
    <phone>82-31-219-5574</phone>
    <email>kjyeop@ajou.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Han Bum Joe, MD</last_name>
    <phone>82-31-219-4916</phone>
    <email>joehanbum@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jong Yeop Kim, MD</last_name>
      <phone>82-31-219-5574</phone>
      <email>kjyeop@ajou.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Han Bum Joe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 28, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jong Yeop Kim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>LMA removal</keyword>
  <keyword>remifentanil</keyword>
  <keyword>propofol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
